The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Golanov A.V.
FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva
Ryzhova M.V.
FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva
Trunin Yu.Yu.
Burdenko Neurosurgical Institute, Moscow, Russian Federation
Zheludkova O.G.
GU FNKTs detskoĭ gematologii, onkologii i immunologii Minzdrava RF im. D. Rogacheva, Moskva
Antipina N.A.
FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva
Cherkesov I.V.
Sechenov University, Moscow, Russia.
Glioblastomas in patients with medulloblastomas after combined treatment
Journal: Burdenko's Journal of Neurosurgery. 2020;84(3): 35‑41
Views: 3242
Downloaded: 54
To cite this article:
Golanov AV, Ryzhova MV, Trunin YuYu, Zheludkova OG, Antipina NA, Cherkesov IV. Glioblastomas in patients with medulloblastomas after combined treatment. Burdenko's Journal of Neurosurgery.
2020;84(3):35‑41. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20208403135
Medulloblastoma (MB) is the most common brain malignancy in children occurring in the posterior cranial fossa. This tumor is characterized by high risk of metastasis along the CSF pathways. Significant progress in research of this tumor and appropriate treatment is associated with determining the various molecular categories of primary medulloblastomas. This analysis includes certain factors of cytogenetic and transcriptional proliferation. Modern treatment approaches for patients older than 3 years include advanced resection, craniospinal irradiation with a boost on the postoperative bed followed by platinum-based chemotherapy. Conventional radiotherapy including craniospinal irradiation results a significant number of complications. Morbidity rate is increased throughout long-term follow-up. Secondary tumors including glioblastomas are under special attention since their occurrence is associated with a fatal outcome. This may partially explaine the fact that chemotherapy without repeated morphological verification doesn’t always ensure tumor growth control in patients with recurrent medulloblastomas. The authors consider irradiation-induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection. It was found that the incidence of this phenomenon is significant and made up about 10% among patients with recurrent medulloblastomas. This value is significantly higher compared to previous data. The authors analyzed patterns of occurrence of irradiation-induced glioblastomas depending on the molecular genetic group and clinical characteristics of patients after primary surgery. Treatment outcomes were estimated too. It was concluded that morphological verification is necessary if long-term recurrence is diagnosed after combined treatment of medulloblastoma.
Authors:
Golanov A.V.
FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva
Ryzhova M.V.
FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva
Trunin Yu.Yu.
Burdenko Neurosurgical Institute, Moscow, Russian Federation
Zheludkova O.G.
GU FNKTs detskoĭ gematologii, onkologii i immunologii Minzdrava RF im. D. Rogacheva, Moskva
Antipina N.A.
FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva
Cherkesov I.V.
Sechenov University, Moscow, Russia.
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.